Pneumococcal Vaccine Polyvalent Market Report

Global Pneumococcal Vaccine Polyvalent Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 09, 2022
  • PAGES：179
  • REPORT CODE：GMM879174
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Pneumococcal Vaccine Polyvalent market report explains the definition, types, applications, major countries, and major players of the Pneumococcal Vaccine Polyvalent market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Merck & Co

    • Pfizer

    By Type:

    • Prevnar 13

    • Pneumovax23

    By End-User:

    • 18 years and younger

    • 19 to 64 years old

    • 65 years and older

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Pneumococcal Vaccine Polyvalent Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Pneumococcal Vaccine Polyvalent Outlook to 2028- Original Forecasts

    • 2.2 Pneumococcal Vaccine Polyvalent Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Pneumococcal Vaccine Polyvalent Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Pneumococcal Vaccine Polyvalent Market- Recent Developments

    • 6.1 Pneumococcal Vaccine Polyvalent Market News and Developments

    • 6.2 Pneumococcal Vaccine Polyvalent Market Deals Landscape

    7 Pneumococcal Vaccine Polyvalent Raw Materials and Cost Structure Analysis

    • 7.1 Pneumococcal Vaccine Polyvalent Key Raw Materials

    • 7.2 Pneumococcal Vaccine Polyvalent Price Trend of Key Raw Materials

    • 7.3 Pneumococcal Vaccine Polyvalent Key Suppliers of Raw Materials

    • 7.4 Pneumococcal Vaccine Polyvalent Market Concentration Rate of Raw Materials

    • 7.5 Pneumococcal Vaccine Polyvalent Cost Structure Analysis

      • 7.5.1 Pneumococcal Vaccine Polyvalent Raw Materials Analysis

      • 7.5.2 Pneumococcal Vaccine Polyvalent Labor Cost Analysis

      • 7.5.3 Pneumococcal Vaccine Polyvalent Manufacturing Expenses Analysis

    8 Global Pneumococcal Vaccine Polyvalent Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Pneumococcal Vaccine Polyvalent Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Pneumococcal Vaccine Polyvalent Export by Region (Top 10 Countries) (2017-2028)

    9 Global Pneumococcal Vaccine Polyvalent Market Outlook by Types and Applications to 2022

    • 9.1 Global Pneumococcal Vaccine Polyvalent Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Prevnar 13 Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Pneumovax23 Consumption and Growth Rate (2017-2022)

    • 9.2 Global Pneumococcal Vaccine Polyvalent Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global 18 years and younger Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global 19 to 64 years old Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global 65 years and older Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Pneumococcal Vaccine Polyvalent Market Analysis and Outlook till 2022

    • 10.1 Global Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.2.2 Canada Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.2.3 Mexico Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.3.2 UK Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.3.3 Spain Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.3.4 Belgium Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.3.5 France Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.3.6 Italy Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.3.7 Denmark Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.3.8 Finland Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.3.9 Norway Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.3.10 Sweden Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.3.11 Poland Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.3.12 Russia Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.3.13 Turkey Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.4.2 Japan Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.4.3 India Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.4.4 South Korea Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.4.5 Pakistan Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.4.6 Bangladesh Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.4.7 Indonesia Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.4.8 Thailand Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.4.9 Singapore Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.4.10 Malaysia Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.4.11 Philippines Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.4.12 Vietnam Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.5.2 Colombia Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.5.3 Chile Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.5.4 Argentina Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.5.5 Venezuela Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.5.6 Peru Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.5.7 Puerto Rico Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.5.8 Ecuador Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.6.2 Kuwait Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.6.3 Oman Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.6.4 Qatar Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.7.2 South Africa Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.7.3 Egypt Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.7.4 Algeria Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

      • 10.8.2 New Zealand Pneumococcal Vaccine Polyvalent Consumption (2017-2022)

    11 Global Pneumococcal Vaccine Polyvalent Competitive Analysis

    • 11.1 Merck & Co

      • 11.1.1 Merck & Co Company Details

      • 11.1.2 Merck & Co Pneumococcal Vaccine Polyvalent Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Merck & Co Pneumococcal Vaccine Polyvalent Main Business and Markets Served

      • 11.1.4 Merck & Co Pneumococcal Vaccine Polyvalent Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Pfizer

      • 11.2.1 Pfizer Company Details

      • 11.2.2 Pfizer Pneumococcal Vaccine Polyvalent Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Pfizer Pneumococcal Vaccine Polyvalent Main Business and Markets Served

      • 11.2.4 Pfizer Pneumococcal Vaccine Polyvalent Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    12 Global Pneumococcal Vaccine Polyvalent Market Outlook by Types and Applications to 2028

    • 12.1 Global Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Prevnar 13 Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Pneumovax23 Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global 18 years and younger Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global 19 to 64 years old Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global 65 years and older Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Pneumococcal Vaccine Polyvalent Market Analysis and Outlook to 2028

    • 13.1 Global Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.2.2 Canada Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.3.2 UK Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.3.3 Spain Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.3.5 France Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.3.6 Italy Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.3.8 Finland Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.3.9 Norway Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.3.11 Poland Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.3.12 Russia Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.4.2 Japan Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.4.3 India Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.5.3 Chile Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.5.6 Peru Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.6.3 Oman Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Pneumococcal Vaccine Polyvalent Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Pneumococcal Vaccine Polyvalent

    • Figure of Pneumococcal Vaccine Polyvalent Picture

    • Table Global Pneumococcal Vaccine Polyvalent Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Pneumococcal Vaccine Polyvalent Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Prevnar 13 Consumption and Growth Rate (2017-2022)

    • Figure Global Pneumovax23 Consumption and Growth Rate (2017-2022)

    • Figure Global 18 years and younger Consumption and Growth Rate (2017-2022)

    • Figure Global 19 to 64 years old Consumption and Growth Rate (2017-2022)

    • Figure Global 65 years and older Consumption and Growth Rate (2017-2022)

    • Figure Global Pneumococcal Vaccine Polyvalent Consumption by Country (2017-2022)

    • Table North America Pneumococcal Vaccine Polyvalent Consumption by Country (2017-2022)

    • Figure United States Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Canada Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Mexico Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Table Europe Pneumococcal Vaccine Polyvalent Consumption by Country (2017-2022)

    • Figure Germany Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure UK Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Spain Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Belgium Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure France Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Italy Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Denmark Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Finland Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Norway Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Sweden Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Poland Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Russia Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Turkey Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Table APAC Pneumococcal Vaccine Polyvalent Consumption by Country (2017-2022)

    • Figure China Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Japan Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure India Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure South Korea Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Thailand Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Singapore Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Philippines Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Table South America Pneumococcal Vaccine Polyvalent Consumption by Country (2017-2022)

    • Figure Brazil Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Colombia Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Chile Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Argentina Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Peru Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Table GCC Pneumococcal Vaccine Polyvalent Consumption by Country (2017-2022)

    • Figure Bahrain Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Oman Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Qatar Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Table Africa Pneumococcal Vaccine Polyvalent Consumption by Country (2017-2022)

    • Figure Nigeria Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure South Africa Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Egypt Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure Algeria Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Table Oceania Pneumococcal Vaccine Polyvalent Consumption by Country (2017-2022)

    • Figure Australia Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Pneumococcal Vaccine Polyvalent Consumption and Growth Rate (2017-2022)

    • Table Merck & Co Company Details

    • Table Merck & Co Pneumococcal Vaccine Polyvalent Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck & Co Pneumococcal Vaccine Polyvalent Main Business and Markets Served

    • Table Merck & Co Pneumococcal Vaccine Polyvalent Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Pneumococcal Vaccine Polyvalent Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Pneumococcal Vaccine Polyvalent Main Business and Markets Served

    • Table Pfizer Pneumococcal Vaccine Polyvalent Product Portfolio

    • Figure Global Prevnar 13 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pneumovax23 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global 18 years and younger Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global 19 to 64 years old Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global 65 years and older Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pneumococcal Vaccine Polyvalent Consumption Forecast by Country (2022-2028)

    • Table North America Pneumococcal Vaccine Polyvalent Consumption Forecast by Country (2022-2028)

    • Figure United States Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Pneumococcal Vaccine Polyvalent Consumption Forecast by Country (2022-2028)

    • Figure Germany Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Pneumococcal Vaccine Polyvalent Consumption Forecast by Country (2022-2028)

    • Figure China Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Pneumococcal Vaccine Polyvalent Consumption Forecast by Country (2022-2028)

    • Figure Brazil Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Pneumococcal Vaccine Polyvalent Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Pneumococcal Vaccine Polyvalent Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Pneumococcal Vaccine Polyvalent Consumption Forecast by Country (2022-2028)

    • Figure Australia Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Pneumococcal Vaccine Polyvalent Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US